EnGen Bio's lead program focuses on developing an effective, easy-to-manufacture, shelf-stable vaccine and therapy to confer long-term immunity to all Type A influenza strains, including all flu pandemics, all Type A seasonal flus, and all animal flus.
Our goal: with one or two shots, you could be protected from the worst seasonal influenza viruses, and all pandemic influenza strains for life. Or, if you have already been exposed or have come down with the flu, our therapy could offer you a treatment.
- Min investment
- Days Left
Redwood City, CA
- Security Type
Membership Units represent ownership rights in a Limited Liability Company, indicated by the right to receive cash or unit distributions, declared by the Manager(s) of the LLC, and having voting rights in the governance of the Company.
- March 11, 2021
- April 30, 2022
- Deal Structure
Price Per Share: $0.586
- 34% towards research and development, 52% towards operations and salary, 8% legal/IP and taxes, 6% Wefunder intermediary fee
- 60% towards research and development, 31% towards operations and salary, 3% legal/IP and taxes, 6% Wefunder intermediary fee
CrowdLustro Research Report
Use of Proceeds
20+yr serial biotech entrepreneur | $600M in corporate deals/transactions | 3 founded pharmaceutical startups | 2 IPO | 1 acquisition | 13 patents | Cornell (BS) | Harvard (MS/PhD Cellular & Developmental Biology) | Post-doctoral Fellowship Stanford
We were developing a universal influenza vaccine and therapy well before the Covid-19 Pandemic started. Our team is driven to identify potentially transformative treatments and preventions for difficult diseases, -flu is a great place to start!
Dr. Mark Baer Vice President of Research
20+yr R&D of therapeutic antibodies | 20+ groundbreaking academic papers | 16 issued patents | Cornell University (BA) | UNC Chapel Hill (PhD Biochemistry) | Post-doctoral fellowship (National Cancer Institute)
Dr. Geoff Yarranton Science Advisor
35+yr biotech veteran | 20+yr C-level exec | 3 FDA-approved pharmaceuticals (Mylotarg, Bexxar, Cimzia) | 2 successful bio/pharma mergers (including IPO) | 36 US patents | University of Leicester (BSc, Hons) | NIMR (PhD) | Post-doctoral fellowship MIT
No reports have been submittedBecome a Reporter